Vital Therapies Provides Clinical and Regulatory Update SAN

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vital Therapies Provides Clinical and Regulatory Update

SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL ), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, today provided an update on its clinical trial programs and regulatory matters.

As of today, 193 of a targeted 200 subjects have been enrolled in VTI-208, the Company's randomized, controlled, open-label Phase 3 clinical trial in alcohol induced liver decompensation. Forty-six clinical sites are now open in the USA, UK, Spain and Australia. The Company expects to complete enrollment around the end of January and remains on track to announce topline data in the second quarter of 2015. The primary endpoint of VTI-208 is overall survival through at least study day 91. If VTI-208 is statistically and clinically successful, the Company plans to submit a Biologics License Application, or BLA, to the Food and Drug Administration (FDA) in the first half of 2016.

The Company continues to expect topline data from both the VTI-210 and VTI-212 clinical trials in 2016. VTI-210, the Company's second Phase 3 trial, is a randomized, controlled, open-label study evaluating the ELAD System in severe acute alcoholic hepatitis (AAH) patients who have failed standard therapy. VTI-212 is a single-arm Phase 2 trial, evaluating the ELAD System in patients with either fulminant hepatic failure or surgery-induced liver failure.

On the regulatory front, the Company recently received approval of its German Clinical Trial Application (CTA) and can now begin to open sites and enroll subjects in its VTI-210 trial. The Company expects to open up to 10 sites in Germany for VTI-210 in the next year, which will augment the existing VTI-210 sites in the USA, UK and Spain.

Additionally, the Company recently received regulatory guidance responses from the FDA concerning its submission regarding chemistry, manufacturing, and controls topics. The Company believes that this guidance, which covered both the biologic and delivery components of ELAD, is consistent with the Company's current plans as well as prior interactions with the agency.

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting treatment of acute liver failure. The Company's lead product-candidate, the ELAD System, is an extracorporeal bio-artificial liver therapy currently in Phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning or implying expectations for our ability to undertake certain development activities such as clinical trial enrollment and the conduct of our clinical trials (including VTI 208 and VTI 210) and the timing of data release and regulatory submissions. Forward-looking statements are based on management's current, preliminary expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements.  Accordingly, these forward-looking statements do not constitute guarantees of future performance and you are cautioned not to place undue reliance on these forward-looking statements.  Risks and uncertainties include, but are not limited to, the Company's dependence on the success of its ELAD system, its sole product candidate; the success or failure of its clinical trials and development programs; difficulty obtaining regulatory approval in the United States or Europe, in particular for a combination product; and the Company's limited experience in conducting pivotal clinical trials and significant issues regarding its clinical trials, including, but not limited to, the successful opening and the continued participation of clinical sites and their ongoing adherence to protocols, assumptions regarding enrollment rates, timing and availability of subjects meeting inclusion and exclusion criteria, changes to protocols or regulatory requirements, the ability to comply with and meet applicable laws and regulations, and unexpected adverse events or safety issues. These and other risks regarding our business are described in detail in our SEC filings, including in our recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. These forward-looking statements speak only as of the date hereof and Vital Therapies, Inc. disclaims any obligation to update these statements except as may be required by law.

Vital Therapies, Inc. Al Kildani Vice President, Investor Relations and Business Development 858-673-6840

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 22

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 20

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 0

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 60

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 78

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 204

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 221

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 0

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 46

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 27

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring AML's Innovative Permanent Magnet Manufacturing

Updated Category News Views 246

Revolutionizing Permanent Magnet Production Advanced Magnet Lab, Inc. (AML) has emerged as a frontrunner in the field of innovative magnet technologies. By harnessing their advanced PM-Wire™ manufacturing process, AML is setting the stage for a broad range of applications that require permanent magnets. This new technology opens avenues for diverse supply chain...

Continue Reading
Harmonic Secures $75 Million Funding to Innovate AI Mathematics

Updated Category News Views 475

Harmonic Secures $75 Million in Series A Funding Harmonic, a Palo Alto-based innovator in artificial intelligence, has just revealed that it successfully raised $75 million in a Series A funding round. This investment values the company at $325 million, led by the well-known venture capital firm Sequoia Capital, alongside significant backing from Index Ventures and...

Continue Reading
Peoria's Mercedes-Benz of Arrowhead Offers Luxury 3-Row SUVs

Updated Category News Views 22

Luxury SUVs with Space and Sophistication When it comes to racking up the mileage in style, finding that sweet spot between luxury and practicality is the holy grail for many car buyers. Right in the heart of Peoria, Arizona, Mercedes-Benz of Arrowhead is rolling out a red carpet for those of us who crave both opulence and utility in one sleek package. Why Third-Row...

Continue Reading
Understanding the Rise in Comfort Systems USA's Short Interest

Updated Category News Views 176

Understanding Comfort Systems USA's Short Interest The short interest of Comfort Systems USA (NYSE: FIX) has seen a notable rise, increasing by 40.65% since the last report. This reflects growing concerns or speculation surrounding the company's stock performance. Currently, approximately 536 thousand shares are sold short, which constitutes 2.18% of the total shares...

Continue Reading
Investigating Today's Top 5 Stocks: Trends and Insights

Updated Category News Views 181

Market Overview Stocks in the U.S. presented a mixed picture recently, with notable fluctuations in the major indexes. The Dow Jones Industrial Average saw a slight dip of 0.1%, closing at 44,837.56, while the S&P 500 remained stable at 6,389.77. Meanwhile, the Nasdaq climbed slightly, gaining 0.3% to end the day at 21,178.58. Top Five Stocks to Watch Today Market...

Continue Reading